MOA
Icotyde ____ _____the IL __ pathway.
Precisely blocks, 23 pathway
Rates of discontinuation were within what % of placebo?
1%
Based on ICONIC Advance 1, ___ in ___ patients had completely clear skin at Week 24?
~1 in 2!
Simplest way to describe a peptide
Short chain of amino acids, small molecule made of a amino ecids
Patricks favorite Ice Cream flavor
Ben & Jerry’s Cherry Garcia
Icotyde has a half life of ____ and is out of the body in ____ days.
12 hours, 3 days
The 4 most common adverse reactions are?
Headache (4.1%) Nausea (1.2%) Cough (1.2%) Tiredness (1.0%)
On average, patients saw what % Mean PASI improvement at week 4?
42%
Date Icotyde was FDA approved
March 18th, 2026 (Some say 17th…)
Icotyde is cleared in the ____ and ____ ____ in the ____ .
Cleared in the kidneys, and not metabolized in the liver
Icotyde has a consistent safety profile across how many people & how many clinical trials?
2300, 4
Nearly __ out of ___ people saw clear or almost clear skin at 4 months for hard to-treat areas (High impact sites)
6 out of 10
The amount of days to discontinue Icotyde when receiving a live vaccine
3 days